935106861
info@markelab.com
Precio
387.5€ (100 µg)
Epcoritamab is a monoclonal antibody biosimilar expressed in CHO cells, targeting CD3E/MS4A1/CD20, Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody technology. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies. Epcoritamab is currently under investigation in a Phase I/II study for multiple hematological B cell malignancies.
Biosimilars
Human
Monoclonal
Human
CD3E/MS4A1/CD20
Human
IgG4 Kappa-Lambda
Unconjugated
Liquid
ELISA, WB
100 µg
1 mg
Recombinant
> 95%
Purified from cell culture supernatants by Protein A/G chromatography.
0.01 M PBS. pH 7.4.
Aliquot and store at -20°C. Avoid repeated freeze/thaw cycles.
No
Shipped within 7-12 working days.
Biosimilars
Precio a consultar
Ver másPrecio a consultar
Ver másPrecio a consultar
Ver más